Skip to main content
GlaxoSmithKline to present data on myeloma candidate

GlaxoSmithKline is scheduled to make three poster presentations this week, including preclinical and early-stage data for its antibody-drug conjugate GSK2857916, or belantamab mafodotin, which targets B-cell maturation antigen in relapsed or refractory multiple myeloma. The presentations will be made at the ongoing meeting of the European Hematology Association in Amsterdam.

Full Story: